Coronarin A 是一种具有口服活性的天然产物,可通过抑制 mTORC1 和 S6K1 来增强 IRS1 活性,具有抗炎活性,并可用于糖尿病研究。
产品编号: MS-G29932 纯度: ≥98.0% CAS No.: 119188-33-9 分子式: C20H28O2 分子量: 300.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Coronarin A 是一种具有口服活性的天然产物,可通过抑制 mTORC1 和 S6K1 来增强 IRS1 活性,具有抗炎活性,并可用于糖尿病研究。

生物实验数据

生物活性 Coronarin A is an orally active natural product that inhibits mTORC1 and S6K1 to increase IRS1 activity, exhibits anti-inflammatory activity, and can be used in diabetes research.
IC50 & Target

mTORC1

 

S6K1

 

体外研究
(In Vitro)

Coronarin A (3-30 μM; 4 or 12 h) stimulates glycogen synthesis through activating PI3K/Akt/GSK3β signaling and inhibits gluconeogenesis by activating ERK-dependent Wnt/β-catenin/TCF7L2 pathway in rat primary hepatocytes.
Coronarin A (1-30 μM; 4 h) increases tyrosine phosphorylation of IRS1 through inhibiting mTOR/S6K1 signaling.

Western Blot Analysis

Cell Line: Primary rat hepatocytes
Concentration: 1, 3, 10 and 30 μM
Incubation Time: 4 h
Result: Increased the Akt and GSK3β phosphorylation dose-dependently. Dose-dependently stimulated the phosphorylation of both ERK1 and ERK2. Increased the phosphorylation of β-catenin and mitogen-activated protein kinase kinase (MEK). Dose-dependently enhanced the tyrosine phosphorylation of IRS1 at Tyr1222, whereas the serine phosphorylation of IRS1 was dose-dependently inhibited. Reduced the phosphorylation of mTOR, S6K1 and S6.

Cell Viability Assay

Cell Line: Primary rat hepatocytes
Concentration: 1, 3, 10, 30, 100 and 300 μM
Incubation Time: 5.5 h or 12 h
Result: Showed no toxicity at 1-30 μM, decreased cell viability after 12 h incubation at 100 μM.
体内研究
(In Vivo)

Coronarin A (30 or 100 mg/kg; i.p. or p.o.; once daily for 22 days) ameliorates hyperglycemia in mice.
Coronarin A (100 mg/kg; p.o.; once daily for 22 days) inhibits the mTOR/S6K1 pathway to activate PI3K/Akt and ERK/β-catenin signaling in livers of ob/ob mice.
Pharmacokinetic properties of Coronarin A after single administrationa in ob/ob mice.

Coronarin A t1/2 (h) tmax (h) Cmax (ng/mL) AUC0-t (ng·h/mL) AUC0-∞ (ng·h/mL) MRT (h)
i.p. 14.8 1.0 1073 4571 11045 21.7
p.o. 3.01 1.0 388 1694 1856 4.88

Data are presented as the mean of three mice.
aCoronarin A was intraperitoneally or orally administered at 30 mg/kg to ob/ob mice.

Animal Model: Male ob/ob mice
Dosage: 30 mg/kg (IP) or 100 mg/kg (PO)
Administration: Oral or intraperitoneal administration, once daily for 22 days
Result: Significantly decreased the non-fasting and fasting blood glucose. Significantly reduced the serum insulin concentration at 15 min after glucose loading, reduced the average daily food intake while the body weight was unaffected. Increased hepatic glycogen content and the expression levels of gluconeogenic gene Pck1 and G6pc were significantly decreased.
Animal Model: Female ob/ob mice
Dosage: 30 mg/kg
Administration: Intraperitoneal or oral administration (Pharmacokinetic Analysis)
Result: Intraperitoneal injection exhibited higher plasma exposure than oral gavage at the same dose of 30 mg/kg, with Cmax value of 1073 and 388 ng/mL, respectively.
性状 固体
颜色 White to off-white

化学信息

分子量 300.44
分子式 C20H28O2
CAS No. 119188-33-9

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 10 mg/mL (33.28 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.3285 mL16.6423 mL33.2845 mL83.2113 mL
5 mM0.6657 mL3.3285 mL6.6569 mL16.6423 mL
10 mM0.3328 mL1.6642 mL3.3285 mL8.3211 mL
15 mM0.2219 mL1.1095 mL2.2190 mL5.5474 mL
20 mM0.1664 mL0.8321 mL1.6642 mL4.1606 mL
25 mM0.1331 mL0.6657 mL1.3314 mL3.3285 mL
30 mM0.1109 mL0.5547 mL1.1095 mL2.7737 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础